BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6722826)

  • 1. Effects of reserpine on prolactin levels and incidence of breast cancer in postmenopausal women.
    Ross RK; Paganini-Hill A; Krailo MD; Gerkins VR; Henderson BE; Pike MC
    Cancer Res; 1984 Jul; 44(7):3106-8. PubMed ID: 6722826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
    Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
    Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of HRT and the subsequent risk of cancer.
    Beral V; Banks E; Reeves G; Appleby P
    J Epidemiol Biostat; 1999; 4(3):191-210; discussion 210-5. PubMed ID: 10695959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of endogenous and exogenous hormones on breast cancer: epidemiology.
    Vessey MP
    Verh Dtsch Ges Pathol; 1997; 81():493-501. PubMed ID: 9474890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
    J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
    Krajcik RA; Borofsky ND; Massardo S; Orentreich N
    Cancer Epidemiol Biomarkers Prev; 2002 Dec; 11(12):1566-73. PubMed ID: 12496045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rauwolfia derivatives and breast cancer.
    Lilienfeld AM; Chang L; Thomas DB; Levin ML
    Johns Hopkins Med J; 1976 Aug; 139(2):41-50. PubMed ID: 957533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.
    Tworoger SS; Sluss P; Hankinson SE
    Cancer Res; 2006 Feb; 66(4):2476-82. PubMed ID: 16489055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risk in the WHI study: the problem of obesity.
    Kuhl H
    Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of benign and malignant breast disorders in women taking hormones (contraceptive pill or hormonal replacement therapy).
    Tzingounis V; Cardamakis E; Ginopoulos P; Argiropoulos G
    Anticancer Res; 1996; 16(6C):3997-4000. PubMed ID: 9042326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disordered nocturnal prolactin regulation in women with breast cancer.
    Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR
    Cancer Res; 1977 Dec; 37(12):4650-4. PubMed ID: 922745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
    Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
    J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
    Olsson HL; Ingvar C; Bladström A
    Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].
    Holtkamp W; von Heyden D; Rauschecker H; Nagel GA
    Schweiz Med Wochenschr; 1983 Oct; 113(41):1513-20. PubMed ID: 6635641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Researchers can now investigate long-term effects of OCs on cancer.
    Rubin GL; Peterson HB
    Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of the epidemiological literature on antidepressant use and breast cancer risk.
    Coogan PF
    Expert Rev Neurother; 2006 Sep; 6(9):1363-74. PubMed ID: 17009923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.